
CXCR2 antibodies target tumors and neutrophils, enhancing immunotherapy in ARID1A-deficient pancreatic cancer
Pancreatic cancer has long been regarded as one of the most difficult cancers to treat, not only because malignant cells are often detected late, but also because the tumor builds a biological environment








